沛嘉医疗(09996.HK) 公布去年度未经审核营运数据,截至2024年12月31日止,全年收入预期达到约6.1亿至6.3亿元人民币,按年增幅介乎38.3%至42.8%,主要归因于期内集团所有神经介入产品线的持续快速增长,以及在中国经导管主动脉瓣置换市场的份额扩大。
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2024/08/23 | 中期业绩 | 无派息 |
2024/03/28 | 末期业绩 | 无派息 |
2023/08/31 | 中期业绩 | 无派息 |
2023/03/31 | 末期业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.